Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SRPT
SRPT logo

SRPT News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

SRPT News

SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14

6d agomoomoo

SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35

6d agomoomoo

SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13

6d agomoomoo

SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23

6d agomoomoo

Sarepta's Promising Data Sparks Market Optimism

6d agostocktwits

SRPT Stock Sees Largest Daily Increase in Almost 8 Years Following Rare Muscle Disorders Study, Yet Wall Street Remains Skeptical

6d agostocktwits

Sarepta Reports Promising Clinical Results for siRNA Programs

6d agoNASDAQ.COM

Precious Metals Stocks Surge, Led by Aura Minerals

6d agoNASDAQ.COM

SRPT Events

03/25 16:30
Major Averages Rise on U.S. Iran Peace Plan
The major averages closed broadly higher following reports that the U.S. has provided a plan to Iran to bring the war to an end, which sent oil prices lower. The Associated Press reported that Iran was given a 15-point proposal from the U.S. to end the conflict, though media have reported that the two sides remain far apart on a resolution and attacks from both sides have continued.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:MerckTerns Pharmaceuticalsfor $53 per share in cashElon Musk's SpaceX will file an IPO prospectus as soon as this week or next,Armexpectsfrom its chips unit in five yearsChewyreportedand provided its outlook for Q1 and FY26JetBlueis exploring a potential merger with rivals,2. WALL STREET CALLS:Armto Outperform from Market Perform at Raymond JamesWolfeGeneral Motorson underappreciated potential tailwindsWedbushRezoluteas worst case scenario seems unlikely for cHIMondelezto Neutral from Buy at Rothschild & Co RedburnEVgowith Neutral from Overweight at JPMorgan3. AROUND THE WEB:Salesforceis skipping raises for its director-level and above employees, Insider reportsA jury found Metaand Googleliable in a social media addiction trial, Reuters saysMeanwhile, Metawill lay off "a few hundred people" across the company on Wednesday, The Information saysSK Hynixplans to spend about $8B on cutting-edge EUV lithography chipmaking tools from ASMLthrough 2027, Bloomberg saysInteland AMDhave each told customers they plan to raise prices across their entire CPU product lines starting in March and April, Nikkei reports4. MOVERS:Sareptarose after announcingfrom Phase 1/2 ascending dose studies of SRP-1001 and SRP-1003Brazegained afterand authorizing a stock repurchase program of up to $100MApogee Therapeuticsfinished higher after announcing aMaze Therapeuticsclosed lower afterand announcing data from its Phase 2 HORIZON trialAdma Biologicsfell for another session afterfrom Culper Research5. EARNINGS/GUIDANCE:Paychexand reaffirmed its guidance for FY26EDAP TMSand backed its guidance for FY26Cognyte, with EPS beating consensusCintasand raised its guidance for FY26QT Imagingand reaffirmed guidance for FY26INDEXES:The Dow rose 305.43, or 0.66%, to 46,429.49, the Nasdaq gained 167.93, or 0.77%, to 21,929.83, and the S&P 500 advanced 35.53, or 0.54%, to 6,591.90.

SRPT Monitor News

Sarepta Therapeutics to Submit New Drug Applications Following Positive FDA Feedback

Mar 25 2026

Sarepta's Stock Drops After Q4 Earnings Miss and CEO Retirement Announcement

Feb 26 2026

Sarepta's Elevidys Shows Significant Efficacy in DMD Study

Jan 26 2026

Sarepta Submits Clinical Trial Application for Huntington's Disease Therapy

Jan 12 2026

SRPT.O Surges Past 5-Day SMA Amid Positive Sentiment

Nov 14 2025

SRPT Earnings Analysis

No Data

No Data

People Also Watch